Uniphar

Uniphar EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Uniphar (UPR.IR) as of Oct 14, 2026 is 12.80. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 10.25 — a change of 24.81% (higher).

EV/OCF

12.80

YoY

24.81%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Uniphar is 2025 12.80 . EV/OCF (Enterprise Value to Operating Cash Flow) of Uniphar was 2024 10.25 . It decreases by 24.81% higher compared to the previous year.

The Uniphar EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-124.92 EUR
Jan 1, 2019
10.29 EUR
Jan 1, 2020
18.04 EUR
Jan 1, 2021
22.99 EUR
Jan 1, 2022
14.73 EUR
Jan 1, 2023
23.90 EUR
Jan 1, 2024
10.25 EUR
Jan 1, 2025
12.80 EUR
The Uniphar EV/OCF history
YEAREV/OCFYoY
12.80+24.81%
10.25-57.10%
23.90+62.29%
14.73-35.95%
22.99+27.44%
18.04+75.36%
10.29-108.24%
-124.92-80.64%
-645.15-1,513.17%
45.65—
Access this data via the Eulerpool API

Uniphar Stock analysis

What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide. The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services. Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases. Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck. In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed. Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uniphar stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Uniphar is 12.80 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Uniphar changed from 10.25 to 12.80, representing a 24.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Uniphar since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Uniphar with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Uniphar

All Key Metrics — Uniphar